{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:33Z","timestamp":1789726293497,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["2020B005"],"award-info":[{"award-number":["2020B005"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40273-025-01564-2","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T01:56:44Z","timestamp":1763603804000},"page":"245-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2608-2900","authenticated-orcid":false,"given":"Isabell","family":"Wiethoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1007-4284","authenticated-orcid":false,"given":"Willem J. A.","family":"Witlox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-570X","authenticated-orcid":false,"given":"Silvia M. A. A.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6432-0431","authenticated-orcid":false,"given":"Michelle","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4274-9258","authenticated-orcid":false,"given":"Micka\u00ebl","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"14","key":"1564_CR1","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138(14):1387\u201398.","journal-title":"Circulation"},{"issue":"9862","key":"1564_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","volume":"381","author":"BJ Maron","year":"2013","unstructured":"Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242\u201355.","journal-title":"Lancet"},{"issue":"4","key":"1564_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79(4):372\u201389.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 2","key":"1564_CR4","doi-asserted-by":"publisher","first-page":"S388","DOI":"10.21037\/cdt.2019.02.01","volume":"9","author":"CM Wolf","year":"2019","unstructured":"Wolf CM. Hypertrophic cardiomyopathy: genetics and clinical perspectives. Cardiovasc Diagn Ther. 2019;9(Suppl 2):S388-s415.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"7","key":"1564_CR5","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2217\/fca-2020-0242","volume":"17","author":"E Hutt","year":"2021","unstructured":"Hutt E, Nissen SE, Desai MY. Unmet needs in the treatment of hypertrophic cardiomyopathy. Future Cardiol. 2021;17(7):1261\u20137.","journal-title":"Future Cardiol"},{"issue":"13","key":"1564_CR6","first-page":"209","volume":"108","author":"C Prinz","year":"2011","unstructured":"Prinz C, Farr M, Hering D, Horstkotte D, Faber L. The diagnosis and treatment of hypertrophic cardiomyopathy. Dtsch Arztebl Int. 2011;108(13):209\u201315.","journal-title":"Dtsch Arztebl Int"},{"key":"1564_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcae092","author":"SAC Schoonvelde","year":"2024","unstructured":"Schoonvelde SAC, Wiethoff I, Zwetsloot P-P, Hirsch A, Knackstedt C, Germans T, et al. Loss of quality of life and increased societal costs in patients with hypertrophic cardiomyopathy: the AFFECT-HCM study. Eur Heart J. 2024. https:\/\/doi.org\/10.1093\/ehjqcco\/qcae092.","journal-title":"Eur Heart J"},{"issue":"37","key":"1564_CR8","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503\u2013626.","journal-title":"Eur Heart J"},{"issue":"10253","key":"1564_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759\u201369.","journal-title":"Lancet"},{"issue":"10","key":"1564_CR10","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","volume":"8","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol. 2023;8(10):968\u201377.","journal-title":"JAMA Cardiol."},{"key":"1564_CR11","unstructured":"Zorginstituut Nederland. Farmacotherapeutisch rapport Mavacamten (Camzyos\u00ae) bij de behandeling van volwassen pati\u00ebnten met symptomatische (NYHA-klasse II-III) hypertrofische obstructieve cardiomyopathie (HOCM). Onderdeel van de beoordeling van geneesmiddelen voor opname in het geneesmiddelenvergoedingssysteem (GVS) 2024."},{"key":"1564_CR12","unstructured":"European Parliament. Towards a Harmonised EU Assessment of the Added Therapeutic Value of Medicines: Policy department A: Economic and scientific policy; 2015."},{"key":"1564_CR13","unstructured":"Wasfy J, Walton, SM, Beinfeld, M, Nhan, E, Sarker J, Whittington, M, Pearson, SD, Rind, DM. Mavacamten for hypertrophic cardiomyopathy: effectiveness and value: institute for clinical and economic review; 2021."},{"issue":"1","key":"1564_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.clinthera.2021.11.006","volume":"44","author":"N Desai","year":"2022","unstructured":"Desai N, Xie J, Wang Y, Sutton MB, Whang J, Fine JT, et al. Projecting the long-term clinical value of mavacamten for the treatment of obstructive hypertrophic cardiomyopathy in the united states: an assessment of net health benefit. Clin Ther. 2022;44(1):52-66.e2.","journal-title":"Clin Ther"},{"key":"1564_CR15","unstructured":"Single Technology Appraisal. Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928]: National Institute for Health and Care Excellence; 2023. Available from: https:\/\/www.nice.org.uk\/guidance\/TA913\/evidence. Accessed 9 Oct. 2025."},{"key":"1564_CR16","doi-asserted-by":"crossref","unstructured":"Cott\u00e9 F-E, Hurst M, Akarkoub S, Ho M, Vernon J, Chambry L, et al. Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective. Eur J Health Econ. 2025.","DOI":"10.1007\/s10198-025-01808-0"},{"key":"1564_CR17","unstructured":"Zorginstituut Nederland. Kostenhandleiding voor economische evaluaties in de gezondheidszorg: Methodologie en Referentieprijzen. Herziene versie 2024. 2024."},{"key":"1564_CR18","unstructured":"Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidzorg. Herziene versie 2024. 2024."},{"key":"1564_CR19","unstructured":"Zorginstituut Nederland. Pakketadvies mavacamten (Camzyos\u00ae) voor symptomatische obstructieve hypertrofische cardiomyopathie. 2024."},{"key":"1564_CR20","doi-asserted-by":"crossref","unstructured":"Wiethoff I, Goversen B, Michels M, van der Velden J, Hiligsmann M, Kugener T, et al. A\u00a0systematic literature review of economic evaluations and cost-of-illness studies of inherited cardiomyopathies. Neth Heart J. 2023.","DOI":"10.1007\/s12471-023-01776-1"},{"issue":"47","key":"1564_CR21","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","volume":"45","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Or\u0119ziak A, Masri A, Barriales-Villa R, Abraham TP, Owens AT, et al. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2024;45(47):5071\u201383.","journal-title":"Eur Heart J"},{"key":"1564_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021;372:n71.","journal-title":"Br Med J"},{"issue":"1","key":"1564_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","volume":"12","author":"F Rader","year":"2024","unstructured":"Rader F, Or\u0119ziak A, Choudhury L, Saberi S, Fermin D, Wheeler MT, et al. Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE Study. EXPLORER-LTE Cohort JACC Heart Fail. 2024;12(1):164\u201377.","journal-title":"EXPLORER-LTE Cohort. JACC Heart Fail."},{"issue":"12","key":"1564_CR24","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/hec.1148","volume":"15","author":"A Brennan","year":"2006","unstructured":"Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295\u2013310.","journal-title":"Health Econ"},{"key":"1564_CR25","doi-asserted-by":"crossref","unstructured":"Ahluwalia M, Liu J, Olivotto I, Parikh V, Ashley EA, Michels M, et al. The clinical trajectory of NYHA functional class i patients with obstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2024.","DOI":"10.1016\/j.jchf.2024.09.008"},{"key":"1564_CR26","unstructured":"European Medicines Agency. Summary of Product Characteristics. CAMZYOS."},{"issue":"1","key":"1564_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012441","volume":"18","author":"MY Desai","year":"2025","unstructured":"Desai MY, Seto D, Cheung M, Afsari S, Patel N, Bastien A, et al. Mavacamten: real-world experience from 22 months of the risk evaluation and mitigation strategy (REMS) program. Circ Heart Fail. 2025;18(1):e012441.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"1564_CR28","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jchf.2014.06.012","volume":"2","author":"PA Vriesendorp","year":"2014","unstructured":"Vriesendorp PA, Liebregts M, Steggerda RC, Schinkel AF, Willems R, Ten Cate FJ, et al. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2014;2(6):630\u20136.","journal-title":"JACC Heart Fail"},{"key":"1564_CR29","unstructured":"Centraal Bureau voor de Statistiek. Levensverwachting; geslacht, leeftijd (per jaar en periode van vijf jaren). 2024; Available from: https:\/\/www.cbs.nl\/nl-nl\/cijfers\/detail\/37360ned. Accessed 16 Jul 2025."},{"issue":"1","key":"1564_CR30","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1080\/13696998.2023.2277076","volume":"26","author":"Y Wang","year":"2023","unstructured":"Wang Y, Gao W, Han X, Jiang J, Sandler B, Li X, et al. Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study. J Med Econ. 2023;26(1):1495\u2013506.","journal-title":"J Med Econ"},{"key":"1564_CR31","unstructured":"Zorginstituut Nederland. Mavacamten. 2025; Available from: https:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/preparaatteksten\/m\/mavacamten. Accessed 16 Jul 2025."},{"issue":"7","key":"1564_CR32","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/j.socscimed.2006.04.018","volume":"63","author":"JJ Polder","year":"2006","unstructured":"Polder JJ, Barendregt JJ, van Oers H. Health care costs in the last year of life - The Dutch experience. Soc Sci Med. 2006;63(7):1720\u201331.","journal-title":"Soc Sci Med"},{"key":"1564_CR33","unstructured":"Zorginstituut Nederland. Ziektelast in de praktijk. De theorie en praktijk van het berekenen van ziektelast bij pakketbeoordelingen. 2018."},{"key":"1564_CR34","unstructured":"iMTA. Disease burden calculator (iDBC). 2025. Available from: https:\/\/www.imta.nl\/tools\/idbc\/. Accessed 16 Jul 2025."},{"key":"1564_CR35","doi-asserted-by":"crossref","unstructured":"Alarid-Escudero F, Krijkamp E, Enns EA, Yang A, Hunink MGM, Pechlivanoglou P, et al. An introductory tutorial on cohort state-transition models in R using a cost-effectiveness analysis example. Med Decis Making. 2023;43(1):3-20.","DOI":"10.1177\/0272989X221103163"},{"key":"1564_CR36","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3389\/fcvm.2023.1252266","volume":"10","author":"G Liu","year":"2023","unstructured":"Liu G, Su L, Lang M. A systematic review and meta-analysis of sex differences in clinical outcomes of hypertrophic cardiomyopathy. Front Cardiovasc Med. 2023;10:2023.","journal-title":"Front Cardiovasc Med."},{"issue":"11","key":"1564_CR37","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","volume":"37","author":"NC B\u00fcy\u00fckkaramikli","year":"2019","unstructured":"B\u00fcy\u00fckkaramikli NC, Rutten-van M\u00f6lken M, Severens JL, Al M. TECH-VER: a verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics. 2019;37(11):1391\u2013408.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1564_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health."},{"issue":"15","key":"1564_CR39","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034069","volume":"13","author":"D Ramonfaur","year":"2024","unstructured":"Ramonfaur D, Gasperetti A, Blake VE, Rivers B, Kassamali AA, Kasper EK, et al. Eighteen-month real-world experience using mavacamten for treatment of obstructive hypertrophic cardiomyopathy in a racially diverse population. J Am Heart Assoc. 2024;13(15):e034069.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1564_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1001\/jamacardio.2019.4534","volume":"5","author":"M Lorenzini","year":"2020","unstructured":"Lorenzini M, Anastasiou Z, O\u2019Mahony C, Guttman OP, Gimeno JR, Monserrat L, et al. Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population. JAMA Cardiol. 2020;5(1):73\u201380.","journal-title":"JAMA Cardiol."},{"issue":"3","key":"1564_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s41669-019-00173-y","volume":"4","author":"GL Di Tanna","year":"2020","unstructured":"Di Tanna GL, Chen S, Bychenkova A, Wirtz HS, Burrows KL, Globe G. Economic evaluations of pharmacological treatments in heart failure patients: a methodological review with a focus on key model drivers. PharmacoEconomics Open. 2020;4(3):397\u2013401.","journal-title":"PharmacoEconomics Open."},{"issue":"2","key":"1564_CR42","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/jamacardio.2022.4427","volume":"8","author":"LE Rohde","year":"2023","unstructured":"Rohde LE, Zimerman A, Vaduganathan M, Claggett BL, Packer M, Desai AS, et al. Associations between New York Heart Association Classification, objective measures, and long-term prognosis in mild heart failure: a secondary analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2023;8(2):150\u20138.","journal-title":"JAMA Cardiol."},{"key":"1564_CR43","doi-asserted-by":"crossref","unstructured":"Desai MY, Wolski K, Owens A, Geske JB, Saberi S, Wang A, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM. Circulation. 2025;151(19):1378\u201390.","DOI":"10.1161\/CIRCULATIONAHA.124.072445"},{"issue":"3","key":"1564_CR44","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/0272989X15586552","volume":"36","author":"J Thorn","year":"2016","unstructured":"Thorn J, Coast J, Andronis L. Interpretation of the expected value of perfect information and research recommendations: a systematic review and empirical investigation. Med Decis Making. 2016;36(3):285\u201395.","journal-title":"Med Decis Making"},{"issue":"15","key":"1564_CR45","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.035993","volume":"13","author":"CJ Coats","year":"2024","unstructured":"Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, et al. Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM. J Am Heart Assoc. 2024;13(15):e035993.","journal-title":"J Am Heart Assoc"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01564-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01564-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01564-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T14:35:21Z","timestamp":1769783721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01564-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01564-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MM has received a research grant and speakers fee from Bristol Myers Squibb, consultancy fees from Cytokinetics and speaker\u2019s fee from Pfizer. The other authors declare that they have no competing conflicts of interest relevant to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All data and materials are available within the article and supplementary resources. Further information may be available by request to the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The Decision Analysis in R for Technologies in Health (DARTH) code is publicly available under\n                      \n                      .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"IW wrote the code, performed the analyses and drafted the manuscript. WW advised during the coding procedure and reviewed the R scripts. MH and SE supervised the development of the model by regularly providing feedback. MM gave input from a clinical perspective and established connections to clinical experts. All authors read, edited and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}